

Table S3 Demographical and clinical characteristics of the schizophrenia subgroups and healthy control group.

Variable	Group				Analysis		
	FEDN ($\leq 1.76\text{ng/mL}$) (34)		HC (478)		Statistic	df	P
	N	%	N	%			
Sex					$\chi^2 = 38.60$	1	P < 0.001
Male	28	82.4%	146	30.5%			
Female	6	17.6%	332	69.5%			
	Mean	SD	Mean	SD			
Age (y)	35.97	13.15	37.87	13.31	F = 0.656	1	P = 0.418
Onset age (y)	27.67	5.00					
BMI (kg/m^2)	21.24	3.17	22.14	2.96	F = 2.890	1	P = 0.090
CPZ dose (mg/d)	525.76	359.31					
PANSS total score	75.03	23.80					
P subscore	16.00	3.33					
N subscore	18.48	7.93					
G subscore	40.54	15.32					

Note:

BMI: Body Mass Index; CPZ, Chlorpromazine; PANSS, Positive and Negative Syndrome Scale; P, positive symptom; N, negative symptom; G, General psychopathology. FEDN: first-episode drug-naïve schizophrenia patients; HC: healthy controls